EMEA-002360-PIP01-18

Key facts

Active substance
Tirzepatide
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0311/2019
PIP number
EMEA-002360-PIP01-18
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Eli Lilly & Company

Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating